Cancer Immunotherapy News and Research

RSS

Researchers develop new approach to predict immunotherapy response in breast cancer patients

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to assess which patients with metastatic triple-negative breast cancer could benefit from immunotherapy.

29 Oct 2024

New CAR T cells offer controlled treatment for solid tumors

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells-;a type of cancer immunotherapy-;that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.

21 Oct 2024

UCLA and Parker Institute renew alliance to advance cancer immunotherapy

UCLA and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their alliance to advance research in cancer immunotherapy and accelerate the development of curative treatments for the most difficult-to-treat cancers.

16 Oct 2024

Distinct immune profiles linked to adverse reactions from immunotherapy

Distinct immune "signatures" in patients who develop adverse events while taking immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side effects, suggests a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

15 Oct 2024

High-fiber diets transform gut microbiome, improving health across multiple diseases

Researchers identified two competing guilds of gut bacteria, one beneficial and one harmful, which can predict health outcomes and treatment success in diseases like type 2 diabetes.

8 Oct 2024

Engineered E. coli shows promise in cancer immunotherapy

Recent research has shown that certain forms of E. coli bacteria tend to colonize hypoxic areas of the body, including tumors, suggesting they might be playing a role in cancer therapeutics.

4 Oct 2024

New treatment proposed for brain metastases resistant to immunotherapy

Researchers at the Spanish National Cancer Research Centre (CNIO) propose a new treatment for brain metastases that respond poorly, or not at all, to immunotherapy, and provide a biomarker to predict in which cases it should be used.

2 Oct 2024

Researchers identify a protein that recharges T cells for long-lasting cancer remission

Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of combining type 1 and type 2 immunity.

30 Sep 2024

Study reveals rising pharmaceutical industry sponsored clinical trials in the U.S.

Researchers at Fred Hutch Cancer Center identified a substantial increase over the past decade in the proportion of patients with cancer in the U.S. who participate in pharmaceutical industry sponsored clinical trials compared to those conducted with federal government support.

27 Sep 2024

Study reveals positive correlation between type 2 immunity and long-term cancer remission

Results from a preclinical study in mice, led by EPFL, and a collaborative clinical study in patients show that the type 2 immune response – associated with parasitic infection and thought to play a negative role in cancer immunity – is positively correlated with long-term cancer remission.

26 Sep 2024

Women remain underserved in cardiovascular disease treatment despite advances

Women in the UK, and elsewhere, are still missing out on vital treatment for their No 1 killer-;cardiovascular disease-;despite significant progress in the medical management of heart disease and stroke, concludes a consensus statement published online in the journal Heart.

24 Sep 2024

Novel delivery platform enhances effectiveness of cancer immunotherapy and reduces side effects

Immunotherapy is a type of cancer treatment that uses the body's own immune system to help fight cancer. This is by stimulating the immune response to recognize and attack cancer cells more effectively.

16 Sep 2024

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

16 Sep 2024

Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

12 Sep 2024

Distinct waves of T cells generated by each dose of combination immunotherapy

A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion.

29 Aug 2024

16 promising postdoctoral scientists awarded Damon Runyon Fellowships for cancer research

The Damon Runyon Cancer Research Foundation has named 16 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

28 Aug 2024

UQ study unlocks potential for advanced bladder cancer immunotherapy

University of Queensland research could lead to a more effective immunotherapy treatment against bladder cancer.

27 Aug 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

Advancements in neoantigen vaccines offer hope for personalized cancer therapy

The saga of cancer treatment is marked by a relentless pursuit of effectiveness against a disease characterized by complexity and adaptability.

19 Aug 2024

New targets for improved cancer immunotherapy

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.

14 Aug 2024